businesspress24.com - Verisante Featured on Business Television (BTV)
 

Verisante Featured on Business Television (BTV)

ID: 1173757

(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 11/22/12 -- Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company will be featured on Business Television (BTV) on November 24 and 25, 2012.

BTV, a half-hour business program, has been profiling innovative companies in North America every week for the past 14 years. Verisante will air on BTV on the following channels:

In Canada

In the United States

A link to the entire feature will be available on the Company's website after the broadcast.

About Verisante Technology, Inc.

committed to . The and the utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, for many of the most common cancers. The Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.

Verisante Aura™ was awarded Popular Science Magazine's "" for 2011, and Verisante Core™ was named one of the of 2011 by the Canadian Cancer Society. In addition, the Company was named a finalist for the by the Canadian Manufacturers & Exporters and the National Research Council of Canada and named as the year's top ranking Technology and Life Sciences Company on the .

Youtube:

Twitter:

Facebook:

Forward-Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.





The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.



Contacts:
Verisante Technology, Inc.
Thomas Braun
President & CEO
(604) 605-0507


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  CONMED Corporation to Present at the 24th Annual Piper Jaffray Healthcare Conference
Mirada Medical Image Analysis Software Selected for Quantitative Tumor Tracking at The Johns Hopkins University
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 22.11.2012 - 09:00 Uhr
Sprache: Deutsch
News-ID 1173757
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

VANCOUVER, BRITISH COLUMBIA


Phone:

Kategorie:

Hospitals, Facilities and Providers


Anmerkungen:


Diese Pressemitteilung wurde bisher 199 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Verisante Featured on Business Television (BTV)
"
steht unter der journalistisch-redaktionellen Verantwortung von

Verisante Technology, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Verisante Technology, Inc.



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 76


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.